AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. Extravasations Extravasations, in particular, are of interest to the U.S.
AuntMinnie
JUNE 14, 2024
Nuclear medicine injection extravasations and medical events will be the focus of the Advisory Committee on the Medical Uses of Isotopes (ACMUI)'s public teleconference on June 17. I hope you won't make that a medical event because that would be ridiculous. Nuclear Regulatory Commission (NRC) rulemaking.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Imaging Technology
AUGUST 29, 2023
The event marks a key milestone in the exclusive Cu-67 supply agreement between both companies. Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Imaging Technology
SEPTEMBER 27, 2023
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,
Imaging Technology
OCTOBER 5, 2023
We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.”
Expert insights. Personalized for you.
75 
Let's personalize your content